The PHARMO Institute, part of Lumanity, delivers research insights into Duchenne’s muscular dystrophy (DMD) and Beckers muscular dystrophy (BeMD), and the PHARMO Data Network offers great research potential for these rare disease populations:

  • 20+ years of follow up across multiple patient healthcare settings

  • ~199 patients identified with DMD and ~245 with BeMD diagnosis within the General Practitioner (GP) database between 2003–2023

  • Clinical laboratory data to identify the target cohort via creatine kinase concentration testing and deeper insights into the genetic makeup of patients via the pathology registry

Our real world data (RWD) is available to address a wide range of use cases from treatment patterns, disease progression, safety, and validation of surrogate endpoints of your trial.

E-mail us at contact@lumanity.com to discuss your research needs.

Download our one-pager

Complete the form to download our one-pager on Duchenne's and Beckers muscular dystrophy.

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.
This field is for validation purposes and should be left unchanged.